These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 25449964)
21. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis. Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463 [TBL] [Abstract][Full Text] [Related]
22. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Patti F; Amato MP; Bastianello S; Caniatti L; Di Monte E; Ferrazza P; Goretti B; Gallo P; Morra VB; Lo Fermo S; Picconi O; Tola MR; Trojano M; Mult Scler; 2010 Jan; 16(1):68-77. PubMed ID: 19995846 [TBL] [Abstract][Full Text] [Related]
23. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
24. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854 [TBL] [Abstract][Full Text] [Related]
25. Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis. Liu C; Blumhardt LD Mult Scler; 2002 Feb; 8(1):10-4. PubMed ID: 11936481 [TBL] [Abstract][Full Text] [Related]
26. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J; Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898 [TBL] [Abstract][Full Text] [Related]
27. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA; Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652 [TBL] [Abstract][Full Text] [Related]
28. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA; Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593 [TBL] [Abstract][Full Text] [Related]
29. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon β. Melanson M; Grossberndt A; Klowak M; Leong C; Frost EE; Prout M; Le Dorze JA; Gramlich C; Doupe M; Wong L; Esfahani F; Gomori A; Namaka M Int J Neurosci; 2010 Oct; 120(10):631-40. PubMed ID: 20942577 [TBL] [Abstract][Full Text] [Related]
40. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]